Los Angeles, California 90077

  • Persian Gulf Syndrome


An open-label clinical outcomes study to determine the safety and efficacy of Sentra AM® and Sentra PM® for post-traumatic stress disorder (PTSD) and Gulf War fibromyalgia.

Study summary:

Male and female military veterans age 18 to 75 experiencing moderate to severe PTSD symptoms including cognitive dysfunction, sleep disorders and mood disorders. Open-label internet questionnaire-based clinical outcomes study. 250 subjects. 60 days from enrollment initiation to completion and study close. Sentra AM- two capsules given orally once daily in the morning for 30 days. Sentra PM- two capsules given orally once daily thirty minutes before bedtime for 30 days. To measure improvement in quality of life determined by the change in SF-36 general health survey. Improvements in daytime sleepiness determined by the Epworth Sleepiness Scale, improvement in cognitive and emotional function using the Cognitive emotion regulation questionnaire - short, change in PTSD symptoms with the Primary Care - PTSD, Psychopathy Checklist- Military. Heart rate variability data variation will be measured in a group of twenty subjects.


Inclusion Criteria: 1. United States military veterans reporting PTSD and/or Gulf War Illness symptoms at least three months after return from duty. 2. Men and non-pregnant, non-lactating women over the age of 18 and under the age of 75, able to read and understand English-language informed consent. 3. Men and women of child-bearing potential willing to use adequate contraception, not to become pregnant or impregnate their partner for the study duration. 4. Patients who will continue on a stable dose (no less than three months) of other medications they are taking and maintain the same dose throughout the duration of the study. 5. Patients willing to commit to completing all clinical questionnaires and guidelines during study-related procedures. Exclusion Criteria: 1. Patients who have previously taken Sentra AM or Sentra PM. 2. Patients not fluent in English. 3. Participation in a clinical trial within one (1) month prior to screening. 4. Uncontrolled or unstable serious cardiovascular, pulmonary, gastrointestinal, endocrine or neurologic disorder.



Primary Contact:

Stephanie Pavlik
Phone: 310-913-1120
Email: subjectinquiry@ptlcentral.com

Backup Contact:

Email: marcusch@ptlcentral.com
Marcus Charuvastra
Phone: 310-474-9809

Location Contact:

Los Angeles, California 90077
United States

Stephanie Pavlik
Phone: 310-913-1120
Email: subjectinquiry@ptlcentral.com

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.